Assembly Biosciences Files 8-K

Ticker: ASMB · Form: 8-K · Filed: Aug 8, 2025 · CIK: 1426800

Assembly Biosciences, INC. 8-K Filing Summary
FieldDetail
CompanyAssembly Biosciences, INC. (ASMB)
Form Type8-K
Filed DateAug 8, 2025
Risk Levellow
Pages3
Reading Time3 min
Key Dollar Amounts$0.001
Sentimentneutral

Sentiment: neutral

Topics: 8-K, reporting

TL;DR

Assembly Bio filed a standard 8-K, no major news.

AI Summary

Assembly Biosciences, Inc. filed an 8-K on August 8, 2025, reporting on other events and financial statements. The filing does not contain specific financial figures or material events beyond the standard reporting requirements.

Why It Matters

This 8-K filing indicates routine corporate reporting by Assembly Biosciences, Inc. without disclosing specific material events or financial updates.

Risk Assessment

Risk Level: low — The filing is a routine 8-K with no disclosed material events, indicating no immediate new risks.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is to report on 'Other Events' and 'Financial Statements and Exhibits' as of August 8, 2025.

What is the exact date of the earliest event reported in this filing?

The date of the earliest event reported in this filing is August 8, 2025.

In which state is Assembly Biosciences, Inc. incorporated?

Assembly Biosciences, Inc. is incorporated in Delaware.

What is the SEC file number for Assembly Biosciences, Inc.?

The SEC file number for Assembly Biosciences, Inc. is 001-35005.

What is the address of Assembly Biosciences, Inc.'s principal executive offices?

The address of Assembly Biosciences, Inc.'s principal executive offices is Two Tower Place, 7th Floor, South San Francisco, California 94080.

Filing Stats: 760 words · 3 min read · ~3 pages · Grade level 11.1 · Accepted 2025-08-08 08:24:47

Key Financial Figures

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Assembly Biosciences, Inc. Date: August 8, 2025 By: /s/ John O. Gunderson John O. Gunderson VP, General Counsel and Corporate Secretary

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing